Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anetumab Ravtansine and Pembrolizumab for Mesothelin-Positive Malignant Pleural Mesothelioma
NCT03126630Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2018
- Primary completion
- May 2023
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of anetumab ravtansine in malignant pleural mesothelioma (MPM) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Objective Response Rate up to 2 years and Recommended Phase 2 Dose up to 2 years. Started Oct 2018; status: active, not recruiting.
02
Drugs
anetumab ravtansine
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT03126630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03126630.